EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nourseothricin as a novel therapeutic agent against Neisseria gonorrhoeae : in vitro and in vivo evaluations using Galleria mellonella —a pilot study

Izumo Kanesaka iD, Said Abdellati, Zina Gestels, Thibaut Vanbaelen, Irith De Baetselier iD, Tessa de Block, Sheeba Santhini Manoharan-Basil iD, Chris Kenyon iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.01275-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Izumo Kanesaka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Anti-Bacterial Agents, Gonorrhea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neisseria gonorrhoeae has developed resistance to multiple antibiotics, making the search for novel antimicrobial agents essential. This pilot study evaluates the in vitro and in vivo efficacy of nourseothricin, a streptothricin family antibiotic mixture primarily composed of streptothricin F, against N. gonorrhoeae , a previously unexplored therapeutic option. The minimum inhibitory concentrations (MICs) of nourseothricin were determined using the agar dilution method on a panel of N. gonorrhoeae strains, including multidrug-resistant isolates. The in vivo efficacy was assessed using the Galleria mellonella infection model, where larvae were infected with N. gonorrhoeae and treated with varying concentrations of nourseothricin. Survival rates were compared to those of ceftriaxone-treated and untreated control groups. Nourseothricin inhibited the growth of all tested N. gonorrhoeae strains, with MIC values ranging from 16 to 32 µg/mL, independent of resistance to ceftriaxone, ciprofloxacin, or azithromycin. In vivo , treatment with nourseothricin significantly improved larval survival compared to the untreated control group ( P < 0.01). The highest survival rate was observed with a 32 µg/mL dose, comparable to that of ceftriaxone-treated groups. Nourseothricin exhibited in vitro activity against N. gonorrhoeae , including multidrug-resistant strains. The in vivo results, obtained in a Galleria mellonella larval model, suggest that nourseothricin may warrant further investigation as a candidate compound for the treatment of gonorrhea, although its clinical potential remains to be evaluated in mammalian systems. IMPORTANCE The emergence of multidrug-resistant Neisseria gonorrhoeae has made the development of new treatments a critical priority. This study is the first to evaluate the in vivo efficacy of nourseothricin against N. gonorrhoeae , demonstrating its activity even against resistant strains. In addition to its in vitro efficacy, treatment with nourseothricin improved survival in an in vivo infection model, suggesting its potential as a therapeutic option. Given the increasing limitations of existing antibiotics, these findings support further investigation into nourseothricin as a candidate for future gonorrhea treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria gonorrhoeaeAnti-Bacterial AgentsGonorrheaAnimalsMicrobial Sensitivity TestsPilot ProjectsDisease Models, AnimalLarvaMothsHumansCeftriaxoneDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Galleria mellonellaNeisseria gonorrhoeaegonorrheanourseothricinstreptothricin F

Substanzen

Anti-Bacterial AgentsCeftriaxone

Autor:innen und Institutionen

  • Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
  • Department of Infection Control and Prevention, Faculty of Nursing, Toho University, Tokyo, Japan.
  • University of Cape Town, Cape town, South Africa.

ORCID-Profile: Izumo Kanesaka, Irith De Baetselier, Sheeba Santhini Manoharan-Basil, Chris Kenyon

Zitieren

APA

Kanesaka, I., Abdellati, S., Gestels, Z., Vanbaelen, T., De Baetselier, I., de Block, T., Manoharan-Basil, S. S., & Kenyon, C. (2025). Nourseothricin as a novel therapeutic agent against Neisseria gonorrhoeae : in vitro and in vivo evaluations using Galleria mellonella —a pilot study. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01275-25

Vancouver

Kanesaka I, Abdellati S, Gestels Z, Vanbaelen T, De Baetselier I, de Block T, et al. Nourseothricin as a novel therapeutic agent against Neisseria gonorrhoeae : in vitro and in vivo evaluations using Galleria mellonella —a pilot study. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01275-25

BibTeX
@article{Kanesaka2025,
  author = {Kanesaka, Izumo and Abdellati, Said and Gestels, Zina and Vanbaelen, Thibaut and De Baetselier, Irith and de Block, Tessa and Manoharan-Basil, Sheeba Santhini and Kenyon, Chris},
  title = {Nourseothricin as a novel therapeutic agent against Neisseria gonorrhoeae : in vitro and in vivo evaluations using Galleria mellonella —a pilot study},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.01275-25}
}
Kostenlos starten →